Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials

Rosalind Raine,1* Wendy Atkin,2 Christian von Wagner,3 Stephen Duffy,4 Ines Kralj-Hans,5 Allan Hackshaw,6 Nicholas Counsell,6 Sue Moss,4 Lesley McGregor,3 Cecily Palmer,1 Samuel G Smith,3 Mary Thomas,1 Rosemary Howe,2 Gemma Vart,3 Roger Band,7 Stephen P Halloran,8,9 Julia Snowball,8 Neil Stubbs,8 Graham Handley,10 Richard Logan,11 Sandra Rainbow,12 Austin Obichere,13 Stephen Smith,14 Stephen Morris,1 Francesca Solmi1 and Jane Wardle3†

1Department of Applied Health Research, University College London, London, UK
2Department of Surgery and Cancer, Imperial College London, London, UK
3Department of Epidemiology and Public Health, University College London, London, UK
4Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
5Department of Biostatistics, King’s Clinical Trials Unit, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
6University College London Cancer Trials Centre, London, UK
7Patient and Public Involvement Representative, Evesham, UK
8NHS Bowel Cancer Screening Programme Southern Hub, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
9Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
10NHS Bowel Cancer Screening Programme North East Hub, Gateshead Health NHS Foundation Trust, Queen Elizabeth Hospital, Gateshead, UK
11NHS Bowel Cancer Screening Programme Eastern Hub, Nottingham University Hospitals, Nottingham, UK
12NHS Bowel Cancer Screening Programme London Hub, Northwick Park and St Marks Hospitals NHS Trust, Harrow, UK
Declared competing interests of authors: none

Disclaimers: this report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published March 2017
DOI: 10.3310/pgfar05080

Scientific summary

Reducing the social gradient in uptake of bowel cancer screening
Programme Grants for Applied Research 2017; Vol. 5: No. 8
DOI: 10.3310/pgfar05080

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Bowel cancer is the third most common cancer in the UK and the second most common cause of cancer death. This significant public health burden can be diminished by screening using the guaiac faecal occult blood test (gFOBt), which reduces bowel cancer mortality by 16% among people offered screening. The NHS Bowel Cancer Screening Programme (BCSP) commenced biennial screening in 2006 and now offers gFOBt to 60- to 74-year-olds in England.

Overall, screening uptake [defined as the return of a gFOBt kit within 18 weeks of the invitation that led to a ‘definitive’ test result of either ‘normal’ (i.e. no further investigation required) or ‘abnormal’ (i.e. requiring referral for further testing, usually colonoscopy)] is about 56%, but uptake varies from 61% in the least deprived to 35% in the most deprived areas of the country. Uptake within South Asian communities further varies: 31.9% in the Muslim community, 34.6% in the Sikh community and 43.7% in the Hindu community when compared with ‘non-Asians’. Previous research to tackle socioeconomic inequalities in uptake has focused on specific underserved groups rather than reducing the gradient in uptake across the entire population.

Therefore, we explored reasons for non-uptake and subsequent uptake of bowel cancer screening in men and women from different socioeconomic backgrounds in England (London and Yorkshire) and in South Asian communities in London (workstream 1). We developed and tested four theoretically derived, novel interventions that aimed to increase uptake among individuals with lower socioeconomic circumstances (SECs) without compromising uptake in any socioeconomic group (workstream 2). We then tested the effectiveness and cost-effectiveness of our interventions in four randomised controlled trials (RCTs), which incorporated the interventions within the NHS BCSP (workstream 3).

Objectives

Overall objective: to reduce socioeconomic inequalities in bowel cancer screening uptake without compromising uptake in any socioeconomic group.

Objectives of each workstream

Workstream 1: to explore psychosocial and cultural determinants of low uptake of gFOBt in the general population and in South Asian communities.

Workstream 2: to develop and test four theoretically based interventions designed specifically to reduce the socioeconomic gradient in bowel cancer screening uptake.

Workstream 3: to use a RCT design to evaluate the effectiveness and cost-effectiveness of each individual intervention within the NHS BCSP.

Workstream 1

Methods

We conducted 18 focus groups with individuals eligible for screening and from a range of socioeconomic backgrounds in London and South Yorkshire. Sixteen groups were recruited via a postal invitation sent from the NHS BCSP. One group was recruited via a community setting and another via a market research recruitment agency.
In addition, we carried out interviews with individuals who acted as key informants for a variety of South Asian communities in London. South Asian communities were chosen because they represent the largest ethnic minority group in England (approximately 7% of the population) and low uptake of colorectal cancer (CRC) screening in the UK has continued to be identified within all South Asian religiolinguistic groups even when age, deprivation and gender are adjusted for. Key informants were purposively sampled to ensure representation from the three dominant faith backgrounds (Islam, Hinduism and Sikhism). Interviews were recorded, transcribed and analysed using thematic analysis.

Results

Focus groups
In all, 128 men and women from diverse occupational backgrounds took part in a focus group. The majority of participants recalled receiving invitation(s) and gFOBt kit(s) from the NHS BCSP. One hundred participants reported gFOBt non-uptake on at least one occasion, of whom 31 went on to complete the gFOBt kit when invited to take part in a subsequent screening round. Nine participants had not completed the gFOBt kit owing to having had investigations outside the NHS BCSP, such as colonoscopy, endoscopy or gFOBt kit completion in primary or private care.

We identified the following themes summarising why people did not to take part in the NHS BCSP: (1) risks to hygiene and personal risk posed by dealing with faeces; (2) detachment from familiar health-care settings; (3) implications of knowing the screening results; (4) judgements of good health and low levels of screening; and (5) delaying uptake leading to non-uptake.

Among individuals who had not taken part in screening in one episode but had subsequently participated, the key ‘tipping point’ that changed their decision was discussions about bowel cancer and screening with their peers.

Key informant interviews
Interviews were conducted with 16 London-based ‘key informants’ representing three South Asian faith communities in order to explore reasons for the variability of low uptake between faith communities and to identify reasons for low uptake of bowel cancer screening in South Asian communities as well as strategies by which uptake might be improved. Twelve key informants held roles in faith, community or charity organisations and four were general practitioners (GPs). Across South Asian faith groups key informants identified limitations posed by the written word, low awareness of CRC and screening, difficulties with handling faeces and gFOBt completion as reasons for low bowel cancer screening uptake. In addition, written materials were deemed particularly inappropriate for the Sylheti-speaking Bangladeshi Muslim community and a social stigma surrounding cancer was described in Sikh communities, which may hinder engagement with screening. Non-written information delivered within faith or community settings was preferred across all faith groups.

Efforts to increase accessibility to bowel cancer screening in South Asian communities should use local ethnic media and face-to-face approaches within community and faith settings to increase awareness of bowel cancer and screening, to address challenges posed by written materials and to challenge the social stigma surrounding cancer.

Workstream 2
We developed and tested four theoretically grounded, simple, low-cost interventions that could easily be implemented within the NHS BCSP.
Intervention 1: a ‘gist’ leaflet
We undertook qualitative research to establish how the existing NHS BCSP materials were received. We then designed a leaflet summarising the key screening information in language suited to respondents with low health literacy and tested the leaflet for readability and comprehensibility via a number of small qualitative studies. Next, we conducted a multicentre RCT with individuals approaching the screening-eligible age \( (n = 4452) \) to examine the impact of the leaflet on intentions to complete screening. We found that inclusion of the gist-based leaflet alongside the standard screening information materials increased knowledge of bowel cancer and bowel cancer screening, but did not increase intention to participate in screening. However, we found that the RCT respondents in both the intervention and control groups had very high intention levels.

Intervention 2: a ‘narrative’ leaflet
We conducted 20 narrative style interviews with individuals who had some experience of taking part in bowel cancer screening. A narrative leaflet based on the ‘stories’ told was developed. The leaflet was particularly consistent with workstream 1 findings concerning resistance to handling faecal matter, the implications of knowing gFOBt results and the power of talk.

We designed the leaflet in consultation with a leading social marketing group and refined the leaflet design before user testing it via a number of focus groups and interviews, which resulted in further minor refinements. We then conducted a multicentre RCT with screening-naive individuals \( (n = 4125) \) to examine the impact of the leaflet on screening intentions. The addition of the narrative leaflet to standard information material had a positive effect on intention to take part in the NHS BCSP and on beliefs about bowel cancer screening, which were previously found to be predictive of intention.

Intervention 3: general practice endorsement
Following insights from the workstream 1 focus groups about the perceived lack of involvement of known and trusted NHS information sources, and in consultation with our Primary Care Advisory Group (five GPs, a practice manager, a NHS BCSP hub director and two clinical academics), we developed text that would appear on the NHS BCSP invitation materials and designed materials to invite GPs to agree to have their practice endorse the NHS BCSP. We then invited all GPs across England to endorse the NHS BCSP. In total, after sending up to three reminder letters, 80% of GPs agreed to endorse the programme.

Intervention 4: enhanced reminder
First, we asked NHS BCSP staff to note details of telephone calls to the NHS BCSP helpline directly relating to the usual reminder letter to assess what issues were raised by potential participants at this stage. We then developed an enhanced reminder (ER) letter to address specific concerns that inhibit test completion, particularly among subjects with lower SECs, including lack of awareness of bowel cancer and of perceived benefits of bowel cancer screening. We then user tested the ER letter in four focus groups \( (n = 26) \).

Workstream 3

Methods
National, cluster-randomised trials compared ‘usual care’ with each of four intervention strategies designed to target known barriers to uptake among people with lower SECs. Each strategy supplemented existing NHS BCSP information/invitation materials with (1) ‘gist’ information \( (n = 163,525) \), a leaflet summarising key information in language suited to respondents with low health literacy; (2) ‘narrative’ information \( (n = 150,417) \), a leaflet describing the experiences of people who had participated in screening; (3) a general practice endorsement (GPE) added to the screening invitation letter \( (n = 265,434) \); and (4) enhancing the reminder letter by reiterating the screening offer \( (ER, n = 168,480) \) sent to initial non-responders. SECs were measured using the Index of Multiple Deprivation (IMD) score associated with each individual’s home address. Change in the socioeconomic gradient in uptake (interaction between treatment group and IMD quintile) was the primary outcome.
Randomisation was based on day of invitation. Trials 1 and 2 (gist and narrative) were run over 10 consecutive days between 5 and 16 November 2012 and 4 and 15 March 2013, respectively. Trials 3 and 4 (GPE and ER) were run over 20 consecutive days between 3 and 28 June 2013 and 8 July and 2 August 2013, respectively. Two weeks before the start of each intervention a randomisation number sequence was generated. For trials 1 and 2, randomisation schedules were sent to REAL Digital International (Croydon, UK) for the Southern, London and Eastern Hubs, and the ‘in house’ invitation system for the North East and Midlands and North West Hubs. For trials 3 and 4, randomisation was undertaken directly through the Bowel Cancer Screening System. Schedules were not provided to the hubs and were instead sent to the Health and Social Care Information Centre (HSCIC), formerly Connecting for Health. Hubs were ‘blind’ to the randomisation schedule and confirmed whether or not the intervention was included on the S1 letter every day, which the trial office then checked against the randomisation schedule. For each set of numbers, days were randomly allocated to the intervention materials plus standard materials or standard materials alone.

Although subsequent blinding was not possible, there was no direct contact with subjects (avoiding biasing participation) and subjects were unaware of the comparator intervention, unless a member of their household received an invitation during the study period that contained different information materials or if they had been invited on a previous occasion and recalled the exact content of the previous invitation.

Findings
Baseline characteristics were well balanced for each trial and representative of the population served by the NHS BCSP. Overall uptake (across the two arms) was 57.4%, 57.7% and 57.9% for trials 1, 2 and 3, respectively, and 25.4% in the ER trial (trial 4), which only targeted individuals who had not responded to the NHS BCSP. Overall uptake (across the two arms) was 57.4%, 57.7% and 57.9% for trials 1, 2 and 3, respectively, and 25.4% in the ER trial (trial 4), which only targeted individuals who had not responded to the NHS BCSP. In all four trial populations, uptake was strongly negatively associated with deprivation, with the difference between the least and most deprived quintiles in each control arm ranging between 20% and 24%.

The effects of the interventions within IMD quintiles are expressed as adjusted odds ratios (ORs). For the gist trial, the difference in uptake between the intervention and control arms was +0.2% in the least deprived group and +1.0% in the most deprived group. The effect did not differ by IMD quintile (least to most deprived quintiles: unadjusted ORs 1.01, 0.99, 1.01, 1.00, 1.04, interaction $p = 0.6$; adjusted ORs 1.06, 1.02, 1.00, 1.01, 1.04, interaction $p = 0.7$). There was no significant increase in overall uptake [unadjusted OR 1.02, 95% confidence interval (CI) 0.92 to 1.13; $p = 0.8$; adjusted OR 1.03, 95% CI 0.99 to 1.06; $p = 0.1$]. The median number of days to return the test kit was 23 in the intervention and 22 in the control arm.

Similarly, for the narrative trial, there was no significant differential effect of the intervention on uptake between the least and most deprived groups (~2.2% and ~3.6%, respectively). The effect did not differ by IMD quintile (least to most deprived quintiles: unadjusted ORs 0.91, 0.97, 0.95, 0.91, 0.86, interaction $p = 0.4$; adjusted ORs 0.98, 1.00, 1.05, 1.00, 0.92, interaction $p = 0.1$). There was also no effect on overall uptake (unadjusted OR 0.93, 95% CI 0.81 to 1.06; $p = 0.3$; adjusted OR 1.00, 95% CI 0.96 to 1.03; $p = 0.8$). The median number of days to return the test kit was 26 in both arms.

In the GPE trial, there was a slight differential change: ~0.8% and +1.4% in the least and most deprived groups. There was also a trend towards a modest SEC gradient in effect; however, this heterogeneity was not significant (unadjusted ORs 0.97, 1.02, 1.06, 1.06, 1.06; $p = 0.3$; adjusted ORs 1.04, 1.06, 1.08, 1.09 and 1.07 for the least to most deprived quintiles respectively; $p = 0.5$). Although the unadjusted OR indicated little effect for overall uptake (unadjusted OR 1.03, 95% CI 0.95 to 1.11; $p = 0.5$), the effect became significant after adjustment for other factors (adjusted OR 1.07, 95% CI 1.04 to 1.10; $p = 0.0001$), mainly owing to differences in effect sizes between arms by screening episode (first time, prevalent, incident). The median number of days to return the test kit was 23 for the intervention and 22 for the control arm.
In the ER trial, the difference in uptake between the intervention and standard arm was \( -0.2\% \) and \( +0.8\% \) in the least and most deprived groups, respectively. There was a significant interaction with IMD quintile (least to most deprived quintiles after adjustment for other factors: unadjusted ORs 0.99, 1.05, 1.10, 1.05, 1.07; \( p = 0.3 \); adjusted ORs 1.00, 1.04, 1.13, 1.09, 1.11; \( p = 0.005 \)) with a greater effect in the most deprived quintile (adjusted OR 1.11, 95% CI 1.04 to 1.20; \( p = 0.003 \)) than the least deprived (adjusted OR = 1.00, 95% CI 0.94 to 1.06; \( p = 0.98 \)). The unadjusted OR did not indicate a statistically significant difference in overall uptake between intervention and control arms (unadjusted OR 1.04, 95% CI 0.95 to 1.14; \( p = 0.4 \)), but the effect became significant after adjustment (adjusted OR 1.07, 95% CI 1.03 to 1.11; \( p = 0.001 \)). The median number of days to return the test kit was 11 in both arms.

The average marginal costs per person screened of providing the gist and narrative leaflets were £0.04 and £0.05, respectively. The GPE and ER trials incurred a one-off cost to modify the standard invitation and reminder letters within the NHS BCSP information technology system of £78,000, but this cost would not be incurred again if the interventions were implemented. The average marginal cost per person screened with these interventions was therefore zero.

**Conclusion**

Three out of four trials of interventions aimed at tackling inequalities in screening uptake failed to reduce the SEC gradient. An ER letter was the only strategy to significantly reduce the gradient, while GPE increased overall uptake. Given their minimal cost, these interventions could be implemented immediately to support the enhanced and equitable delivery of cancer screening within the NHS BCSP. The results of these trials are testament to the difficulty of modifying inequalities in screening within an organised programme, but they highlight the importance of continuing to research effective strategies to achieve equity in early diagnosis of cancer.

**Trial registration**

This trial is registered as ISRCTN74121020.

**Funding**

Funding for this study was provided by the Programme Grants for Applied Research programme of the National Institute for Health Research.
Programme Grants for Applied Research

ISSN 2050-4322 (Print)
ISSN 2050-4330 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Programme Grants for Applied Research journal

Reports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Programme Grants for Applied Research programme

The Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.

The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.

For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-for-applied-research.htm

This report

The research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0609-10106. The contractual start date was in March 2011. The final report began editorial review in March 2015 and was accepted for publication in May 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PGfAR programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-for-applied-research.htm
Programme Grants for Applied Research Editor-in-Chief

Professor Paul Little  Professor of Primary Care Research, University of Southampton, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk